Xalkori Alternatives Compared
| Xalkori (crizotinib) | Nivolumab | Rybrevant (amivantamab) |
|
|---|
| Xalkori (crizotinib) | Nivolumab | Rybrevant (amivantamab) |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Anaplastic Large Cell Lymphoma - ALK-Positive, Inflammatory Myofibroblastic Tumor, Non Small Cell Lung Cancer. Xalkori may also be used for purposes not listed in this medication guide. View more |
Prescription only
Prescribed for Head and Neck Cancer, Esophageal Carcinoma, Hepatocellular Carcinoma, Colorectal Cancer, Gastric Cancer, Hodgkin's Lymphoma, Malignant Pleural Mesothelioma, Melanoma, Melanoma -... View more |
Prescription only
Prescribed for Non Small Cell Lung Cancer. Rybrevant may also be used for purposes not listed in this medication guide. |
Related suggestions Popular comparisons
|
|||||||||||||||
| More about Xalkori (crizotinib) | More about Nivolumab | More about Rybrevant (amivantamab) | ||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||
|
Xalkori has an average rating of 9.3 out of 10 from a total of 4 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
Nivolumab has an average rating of 5.6 out of 10 from a total of 130 ratings on Drugs.com. 49% of reviewers reported a positive effect, while 44% reported a negative effect. |
Rybrevant has an average rating of 8.5 out of 10 from a total of 4 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
||||||||||||||||
| Drug Class | ||||||||||||||||||
| Side Effects | ||||||||||||||||||
| Generic Availability | ||||||||||||||||||
|
N/A |
N/A |
|||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
View all Xalkori prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Rybrevant prices |
||||||||||||||||
| Dosage Forms Available | ||||||||||||||||||
|
N/A |
|
||||||||||||||||
| Brand Names | ||||||||||||||||||
|
N/A |
Opdivo |
N/A |
||||||||||||||||
| Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||
|
42 hours |
640.8 hours |
271.2 hours |
||||||||||||||||
| CSA Schedule ** View glossary of terms | ||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | ||||||||||||||||||
|
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | ||||||||||||||||||
|
A total of 786 drugs are known to interact with Xalkori:
|
A total of 402 drugs are known to interact with Nivolumab:
|
A total of 14 drugs are known to interact with Rybrevant:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||
| Disease Interactions | ||||||||||||||||||
| First Approval Date | ||||||||||||||||||
|
August 26, 2011 |
December 22, 2014 |
N/A |
||||||||||||||||
| WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||
| More Information | ||||||||||||||||||
| Patient resources | ||||||||||||||||||
| Professional Resources | ||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.